Bright Minds Biosciences (XCNQ:DRUG) ROCE % : -23.57% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bright Minds Biosciences's annualized ROCE % for the quarter that ended in Mar. 2025 was -23.57%.

Bright Minds Biosciences ROCE % Historical Data

The historical data trend for Bright Minds Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences ROCE % Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Sep24

ROCE %

-65.16

-87.29

-99.78

-85.82

-46.38

Bright Minds Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-38.10	15.95	-54.20	-20.47	-23.57

Bright Minds Biosciences ROCE % Calculation

Bright Minds Biosciences's annualized ROCE % for the fiscal year that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	-2.823	/	( ( (6.879 - 0.281)	+	(6.105 - 0.529) )	/ 2 )
	=	-2.823	/	( (6.598	+	5.576)	/ 2 )
	=	-2.823	/	6.087
	=	-46.38 %

Bright Minds Biosciences's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-13.408	/	( ( (58.399 - 0.462)	+	(56.469 - 0.638) )	/ 2 )
	=	-13.408	/	( ( 57.937	+	55.831 )	/ 2 )
	=	-13.408	/	56.884
	=	-23.57 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Bright Minds Biosciences (XCNQ:DRUG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bright Minds Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DRUG:USA

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Executives

Jan Torleif Pedersen	Director
Nils Bottler	Director
Ryan Cheung	Senior Officer
Jeremy Fryzuk	Director
Alan Kozikowski	10% Security Holder, Director, Senior Officer
Ian Mcdonald	Director